About: Tildrakizumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease.

Property	Value
dbo:abstract	Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease. (en) Тилдракизумаб — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (март 2018 года). (ru)
dbo:alternativeName	Ilumya, Ilumetri (en)
dbo:casNumber	1326244-10-3
dbo:drugbank	DB14004
dbo:fdaUniiCode	DEW6X41BEK
dbo:kegg	D10400
dbo:medlinePlus	a618026
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/tildrakizumab
dbo:wikiPageID	36964648 (xsd:integer)
dbo:wikiPageLength	14594 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1090573271 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Schering-Plough dbr:Cytokine dbr:Interleukin-23_receptor dbr:Interleukin_23 dbr:Monoclonal_antibody dbr:Phase_III_clinical_trials dbr:Subcutaneous_injection dbr:Keratinocyte dbr:Almirall dbr:European_Commission dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Psoriasis_Area_and_Severity_Index dbc:Monoclonal_antibodies dbc:Merck_&_Co._brands dbr:Sun_Pharmaceutical dbr:Autoimmune_disease dbr:Plaque_psoriasis dbr:Merck_&_Co. dbr:Major_adverse_cardiovascular_events dbr:Immune_system dbr:Interleukin-23
dbp:atcPrefix	L04 (en)
dbp:atcSuffix	AC17 (en)
dbp:c	6426 (xsd:integer)
dbp:casNumber	1326244 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:dailymedid	Tildrakizumab (en)
dbp:drugbank	DB14004 (en)
dbp:h	9918 (xsd:integer)
dbp:kegg	D10400 (en)
dbp:legalCa	Rx-only (en)
dbp:legalEu	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:mabType	mab (en)
dbp:medlineplus	a618026 (en)
dbp:n	1698 (xsd:integer)
dbp:o	2000 (xsd:integer)
dbp:pregnancyAu	B1 (en)
dbp:routesOfAdministration	dbr:Subcutaneous_injection
dbp:s	46 (xsd:integer)
dbp:source	zu/o (en)
dbp:synonyms	Tildrakizumab-asmn; tildrakizumab (en)
dbp:target	dbr:Interleukin_23
dbp:tradename	Ilumya, Ilumetri (en)
dbp:type	mab (en)
dbp:unii	DEW6X41BEK (en)
dbp:wikiPageUsesTemplate	dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Interleukin_receptor_modulators dbt:Drugs.com dbt:Monoclonals_for_immune_system dbt:Immunosuppressants
dcterms:subject	dbc:Monoclonal_antibodies dbc:Merck_&_Co._brands
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union. Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease. (en) Тилдракизумаб — лекарственный препарат, моноклональное антитело. Одобрен для применения: США (март 2018 года). (ru)
rdfs:label	Tildrakizumab (en) Тилдракизумаб (ru)
owl:sameAs	freebase:Tildrakizumab yago-res:Tildrakizumab wikidata:Tildrakizumab dbpedia-ru:Tildrakizumab https://global.dbpedia.org/id/Yj33
prov:wasDerivedFrom	wikipedia-en:Tildrakizumab?oldid=1090573271&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Tildrakizumab
is dbo:wikiPageRedirects of	dbr:Ilumetri dbr:Ilumya dbr:Tildrakizumab-asmn
is dbo:wikiPageWikiLink of	dbr:Interleukin_23 dbr:Almirall dbr:Erica_Shaffer dbr:ATC_code_L04 dbr:Sun_Pharma dbr:Ilumetri dbr:Ilumya dbr:List_of_therapeutic_monoclonal_antibodies dbr:Tildrakizumab-asmn
is foaf:primaryTopic of	wikipedia-en:Tildrakizumab